-
-
-
|
-
- This
is how the two companies now look.
Hewlett Packard continues to represent computing and imaging products:
enterprise and personal computers, LaserJet, and InkJet products.
-
- Agilent
Technologies focuses on measurement products. Our
groups include test and measurement and semiconductor products, which
have a large interest in the cellular telephone and other
telecommunications businesses.
-
- And, of course, the areas we’ve been discussing today, the
business of Life Sciences, in which includes Healthcare Solutions and
Chemical Analysis groups both play a role.
-
-
-
-
-
|
-
- These
are our core businesses
-
|
-
- You
can take the patient’s information with you.
- This
slide shows how HP can meet your needs anywhere in the continuum, from
point of crisis to home.
-
|
-
-
- That
is where the innovation has been going. In the 80s it was still
separated. In the 90s we combined diagnostics and monitoring. But,
there’s still a piece left in the patient assessment picture.
- Let’s
look at how you assess a patient. You do the diagnostic workup, you do
a series of tests, you form your hypothesis to come up with a
diagnosis. You start the treatment plan, and monitor to see how well
the therapy is received. Then 1-2, 5-10, 24 hours later you find out
that the patient is not moving in the direction you’d like. So, you
re-evaluate your hypothesis. Now you need further diagnostic workup,
reinitiate different therapies and continue to monitor.
- Today’s
therapies and drugs are so potent you just can’t administer these
without understanding what the effects on the patient is going to be.
That’s why you’re seeing more and more merging of technologies in
the industry: pharmaceutical and diagnostics are starting to merge;
diagnostics, therapeutics and monitoring are starting to merge. We’re
doing more and more significant things to patients, so you want to
make sure your doing what’s most appropriate. That’s where the future is going.
-
-
- [Click
for next slide.]
-
-
|
-
- [Speaker’s
notes]
With the products and philosophy of HP Viridia Anesthesia Care in mind,
let’s look back at the anesthesia/surgery care continuum to see how
it all works together.
Viridia monitors begin gathering vital patient information even before
the patient enters Pre-OP. For example, the new Viridia Patient Care
System offers comprehensive patient monitoring and information
management to all areas of your healthcare environment — from the OR to the laboratory to the emergency department.
So once patient data is in the system, it moves with the patient. This
means that when an anesthetic professional conducts the Pre-OP
interview, he has access to critical patient information.
ORVue Pre-OP then offers a convenient and consistent way to perform
the interview and capture that data. ORVue Pre-OP also provides
instant access to pre-anesthetic records and speeds the care
management process. The result: more efficient patient assessment and
more accurate and thorough documentation, which can result in
increased reimbursements.
-
-
|
-
-
-
|
-
- Ongoing
Updateability / Component
Modularity
- The
Agilent Patient Monitors are the only modular systems that allow you
to readily update your software and hardware to meet changing clinical
and business needs. Our “Monitor for Life” philosophy allows you
to invest in state-of-the-art technology and protect that investment.
As new capabilities become available, you can update your system by
adding the new technology or applications. Over the past decade,
thousands of Agilent customers around the world have benefited from
our “update, don’t replace” strategy.
-
-
|
-
-
-
|
-
- The
CMS 2001 features the EASI™ 12-lead ECG technology, a unique ECG monitoring solution that derives a 12-lead ECG
from only five easy-to-place electrodes, and can be used as a
practical and integral part of patient care. EASI delivers essential
clinical information that can be readily implemented by nurses to
provide enhanced patient comfort.
-
- The
EASI 12-lead solution uses five electrodes and three vectors to derive
a 12-lead ECG. The innovative five-lead hook-up utilizes easy-to-find
landmarks to improve application compliance and patient comfort. In
addition, the EASI lead placement generates smaller amounts of
movement artifact than does a 10-electrode lead set.
-
- Up
to three continuous ECG waveforms can be displayed on the monitor
screen along with other monitored parameters, and a 12-lead ECG can be
displayed at any time. The system can be configured to print a 12-lead
ECG automatically in the event of an alarm and at regularly scheduled
intervals.
-
-
-
|
-
- The
EEG module enables fully integrated neurological monitoring for
critical and cardiac, anesthesia, and neonatal care.
- The
EEG module features two-channel raw wave and Compressed Spectral Array
(CSA), which displays EEG data for ease of interpretation, including
derived parameters, continuous electrode impedance check, and manual
or scheduled report capability to local or central printer. Five
user-specific electrode montages can be configured for quick and east
set-up, with graphical representations of electrode locations, as well
as real-time electrode-to-skin impedance-level indication.
- The
EEG module monitors the patient’s cerebral function by measuring the
electrical activity of the brain. It produces two channels of EEG
real-time waves and calculates eight numerics, two of which can be
selected for continuous display, trending, and recording.
- [Note
to presenters: the points below are to familiarize you with an EEG and
may not necessary if speaking to a medical audience]
- By
monitoring the patient’s electroencephalograph (EEG), you are able
to :
- Identify
neurological changes
- Prevent
brain damage by early warnings
- Titrate
the appropriate dosage of therapeutic medication
- Determine
coma prognosis or the extent of cerebral insult
- Synthesize
neurological and physiological information
- Recognize
changes in patient consciousness
-
-
-
-
|
-
- I sistemi diagnostici, posizionati nei
vari settori del DEA (Terapia intensiva, Pronto soccorso, Sale
operatorie) sono interfacciati fra loro in modo che i risultati siano
visibili al clinico; I sistemi poi afferiscono via rete locale (LAN) o
con Modem al sistema di gestione centralizzato del laboratorio (LIS)
e/o ospedaliero (HIS).
-
|
-
- Too
often there’s a disconnect between the availability of physiological
information and clinical laboratory data. If you need physiological
information, you look at the monitor to analyze vital signs, but to
get lab information you turn to the LIS (laboratory information
system) terminal. In some cases, that means a wait of 1, 2, or 3 hours
before the lab work is available. In the meantime, the clinical team
has scattered. These scenarios can’t be tolerated in today’s
quality and cost-conscious environment.
- To
truly lower costs, lower lengths of stay and improve patient outcomes,
the integration of these pieces of information need to be closer and
closer. The team’s together the patient’s presenting, you want all
the information, right
there - right then, right now Hunting for or retrieving information is
obsolete. That’s what we mean when we say The Power to Know. Now.,
when we talk about HP’s point-of-care diagnostics products.
-
|
-
-
- While
costs and outcomes have always been important, the 1990s have seen
difficult challenges. Today you are forced to balance costs with
outcomes. To respond we’ve brought the clinical laboratory to your
patient’s side and taken it one step further with the HP Blood
Analysis Module, which I’ll touch on in a moment.
- We’re
not building technology for technology’s sake. Here the key is using
technology as an enabler to help you diagnose and treat quicker,
reduce costs, improve efficiencies and improved patient outcomes.
-
-
|
-
- As
we add new assays to our menu, they will address needs of the
intensive care market where rapid access to test results will enable a
higher degree of therapy management and the active titration of drug
therapy.
- For
example, the introduction of specific markers of disease at the point
of care, such as cardiac markers, will give clinicians more control of
therapy.
- The
question we ask ourselves during test development and partner
acquisition is simple: What information will streamline protocol and
make a clinical contribution in therapy management?
- Moving
forward, we intend to add other such assays for trauma and emergency;
surgical; and adult, pediatric, and neonatal intensive care
applications.
- For
example, coagulation results may not be required stat all the time;
however, for certain populations, such as ER patients, rapid access to
coag results at the point of care will add an unsurpassed level of
convenience and control for assessing condition/status.
- Point
of care diagnostics has comparable accuracy and precision as large
laboratory instrumentation. Point of care diagnostics can contribute
to decreased overall costs. The addition of measurements like
coagulation, also illustrate the convenience and control benefits
point of care delivers.
- The
point of care menu of the near future will not be complete, but in
many care areas, it will closely match the menu of the tests where
rapid access to results can make a significant clinical difference
through increased control.
-
|
-
- Agilent’s
present information interface includes a VueLink cable interface
between our point of care solutions [both IRMA and Trendcare] and the
patient monitor. [Phase I]
-
- Moving
forward, we will offer configured module for the IRMA/blood analysis
system. We will provide VueLink cable interfaces for measurement from
our new partners. [Phase II]
-
- And
ultimately, as this diagram illustrates, our phased plan progresses
toward a fully modular system where measurements and functionality
will become part of an integrated point of care measurement platform
used at the patient’s side [Phase III]
-
- [Note:
the integrated point of care measurement platform will include two
parts: the “plug-in” module and a cable-connected “station.” [pictured,
center]]
-
- [Do
not to equate the old I-STAT BAM and the new measurement platform
formats. The new “integrated point of care measurement platform”
will look different and have a somewhat different use model. It will,
however, be integrated with Agilent’s monitoring system.]
-
|
